Citeline looks at the top 5 cancers in all Asian countries for both genders in terms of age-standardized rates of incidence and mortality according to GLOBOCAN 2012. Using data exported from Citeline’s competitive intelligence product suite in April 2014, an analysis of over 6500 trials from 1988 to 2014 in these five prevalent Asian cancers include locations, sponsorship, recent clinical activity, primary drugs and mechanisms of action, primary endpoints and incorporation of pharmacogenomic biomarkers.

For more information about Citeline, or other available white paper reports, please visit Citeline here.

For the full report, please download the PDF version at the top of this page.